Genomic testing evaluates sets of genes and gene interactions with respect to disease processes and treatment, especially applied in cancer prediction, diagnostics, prognostics and treatment selection.
Pharmacogenomics (PGx) is the use of genetic information in tailoring or predicting drug response whereas Pharmacogenetics associates drug interaction with an individual's genotype.
The coupling of genomic or genetic testing with the use of FDA-approved drugs results in a companion diagnostic where the drug targets a certain marker or genetic mutation associated with a patient's response. For a current listing of FDA approved companion diagnostics click here.
A-Z Molecular Diagnostic Oncology Tests
ABL Kinase Gene Mutation Analysis; Gleevec® Resistance*
ALK 2p23 rearrangement by FISH
ALK Anaplastic Lymphoma Kinase -1 by IHC
ATM/CEP11 deletion 11q22.3 by FISH
BCR/ABL qRT PCR, Major p210 and Minor p190 Mutations, Minimal Residual Disease
BRAF Mutation Analysis by Next Generation Sequencing
Colon Cancer Panel by Next Generation Sequencing
EGFR amplification (7p11.2) by FISH*
EGFR Mutation Analysis by Next Generation Sequencing
EGR1 5q deletion, monosomy 5 by FISH
Estrogen Progesterone Receptors by IHC
HER2/neu breast cancer by FISH
HER2/neu gastric cancer by FISH
IgVH Somatic Hypermutation by Next Generation Sequencing
← prev 2 next →